Trial Profile
Safety Study of GSK Biologicals' Human Papillomavirus Vaccine (GSK-580299) in Healthy Female Subjects.
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 07 Sep 2023
Price :
$35
*
At a glance
- Drugs Human papillomavirus vaccine recombinant bivalent Japan Vaccine/MedImmune (Primary)
- Indications Cervical cancer; Human papillomavirus infections
- Focus Adverse reactions
- Sponsors GlaxoSmithKline; GSK